# The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

> **NCT05263986** · PHASE1 · UNKNOWN · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumor

## Interventions

- **DRUG:** MRTX849

## Key facts

- **NCT ID:** NCT05263986
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-30
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263986, "The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05263986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*